• Masumbuko Claude Kasereka, Julia Sawatzky, and Michael T Hawkes.
• Université Catholique du Graben, Butembo, Democratic Republic of the Congo.
• Vaccine. 2019 Apr 10; 37 (16): 2174-2178.

BackgroundThe current Ebola outbreak in Eastern Democratic Republic of the Congo (DRC) is the second largest in history and the first in which the recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus (rVSV-ZEBOV) vaccine has been used at scale. We assessed side-effects, satisfaction, and attitudes toward the new vaccine.MethodsCross-sectional survey questionnaire from a convenience sample of 90 vaccine recipients and 96 community controls in Eastern DRC.ResultsSide-effects were reported in 75/90 (83%) vaccine recipients but only 5 (7%) and 4 (5%) reported arthralgia and rash, respectively. 76/90 (84%) vaccinees were classified as "promoters" (would recommend vaccine to others) and 6/90 (7%) as "detractors." 69/96 (72%) of unvaccinated community controls would wish to be vaccinated if supply were available. 153/186 (82%) would accept vaccination for family members.ConclusionsThe rVSV-ZEBOV vaccine was well tolerated, with high acceptability in the community during the current outbreak in the DRC.Copyright © 2019 Elsevier Ltd. All rights reserved.

32 keywords...

hide…